NuCana plc NCNA 深 沪
等待开盘 12-20 09:30:00 美东时间
3.53
+0.060
+1.73%
华盛通- 最 高3.5799
- 今 开3.45
- 成交量 4.61万股
- 最 低 3.4499
- 昨 收 3.47
- 总市值 673.56万
- 52周最高 330.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.78
- 委 比 95.35%
- 总股本 190.81万
- 历史最高 160000.00
- 量 比 1.18
- 振 幅 3.75%
- 历史最低 3.4499
- 每 手 1
- 风险率 92.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
NuCana plc presented clinical data at the 2025 ESMO Immuno-Oncology Congress showing continued activity of NUC-7738 in combination with pembrolizumab for PD-1 inhibitor-resistant metastatic melanoma. Results included two partial responses, seven stable disease cases, and no new safety signals. These findings support the potential benefit of NUC-7738 for patients with advanced melanoma, with further enrollment and clinical advancement planned.
12-10 13:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 18.6% to $2.1...
11-21 05:06
NuCana GAAP EPS of £0.00
NuCana press release (NCNA): Q3 GAAP EPS of £0.00. NuCana reported a net loss of £0.3 million for the quarter ended September 30, 2025, which includes other income of £2.7 million, as compared to a ne...
11-14 05:54
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
NuCana plc announced positive data for its anti-cancer medicines NUC-7738 and NUC-3373, supporting their potential to improve treatment outcomes. Initial data from the expansion study of NUC-7738 is expected in Q4 2025, with final data in 2026. The company is well-capitalized, with cash runway into 2029. NuCana reported a net loss of £0.3 million for Q3 2025 and £26.9 million for the first nine months, but raised £38.4 million via its ATM program...
11-13 21:01
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
NuCana plc announced that China's National Intellectual Property Administration granted a key patent for NUC-7738, a novel anti-cancer agent in Phase 1/2 clinical trials for melanoma. This patent strengthens the company's global intellectual property strategy and supports innovative cancer therapies in China. NUC-7738, which disrupts RNA polyadenylation, is being studied in combination with pembrolizumab.
11-05 13:00
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
NuCana presented data at ESMO 2025 showing NUC-7738 enhances PD-1 inhibitors' effectiveness in patient-derived organoids from renal cell carcinoma, increasing tumor cell death. This combination targets tumor microenvironment aspects, offering potential benefits for anti-PD-1 refractory cancers. The study supports NUC-7738's mechanism, safety, and efficacy seen in NuTide:701 clinical results, including tumor reduction and prolonged survival in PD-...
10-18 12:00
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
NUC-3373, a thymidylate synthase inhibitor, combined with pembrolizumab, shows promising efficacy and safety in heavily pre-treated patients with advanced solid tumors. A patient with bladder urothelial carcinoma experienced a 100% reduction in tumor lesion size, while a melanoma patient achieved an 81% reduction in target lesions and remains progression-free at 23 months. Preclinical data support NUC-3373's immunogenic effects, including DAMP re...
10-14 12:00
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gain...
10-08 20:01
Achieve Life Sciences strengthens leadership team with new COO
Achieve Life Sciences (NASDAQ:ACHV) promoted Craig Donnelly to COO. Mr. Donnelly will lead the supply chain and manufacturing activities with the commercial strategy ahead of a product launch in mid-l...
09-18 23:46
